COVID-19

Authors: Pham TM, Westerhof I, Bootsma MCJ, Kretzschmar ME, Rozhnova G, Bruijning-Verhagen P.

Published in: MedRxiv

Authors: Pagliari M, Mazzetto E, Gastaldelli M, Bortolami A, Donà D, Padoan A, Di Chiara C, Pezzani MD, Cosma C, Napolitan A, Quaranta EG, Giussani E, Fusaro A, Pascarella M, Aita A, Liberati C, Lorusso A, Monne I, De Rossi A, Basso D, Porru S, Ricci A, Terregino C, Plebani M, Tacconelli E*, Giaquinto C*, Bonfante F*.

Published in: Lancet Preprints

One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus

The RBDCOV project, in which Penta is a partner, started a Phase III clinical trial of the Covid-19 vaccine in immunocompromised people, after the Spanish Agency for Medicines and Health Products (AEMPS) authorised it on 9 May. This clinical trial will determine whether an additional dose of HIPRA’s Covid-19 vaccine can generate an immune response in people living with immune system disorders,

Authors: Colosi E, Bassignana G, Contreras DA, Poirier C, Boëlle PY, Cauchemez S, Yazdanpanah Y, Lina B, Fontanet A, Barrat A, Colizza V

Published in: The Lancet

Authors: Di Chiara C, Mengato D, De Pieri M, Longo G, Benetti E, Venturini F, Giaquinto C and Donà D.

Published in: Children

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.                

“RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA.

Penta is proud to be a partner in the Horizon Europe funded “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) project. Within the project we will be bringing our paediatric expertise and drive to improve health outcomes for children.

During the project’s 2.5-year duration, RBDCOV will test the efficacy, tolerability, and safety of the Covid-19 vaccine in children, adolescents and immunocompromised people.

Read the RBDCOV press release for more on the project.

Today we launch VERDI, a project that prioritizes women and children in the research on new coronavirus variants

The University of Padua and Penta Foundation are leaders of VERDI, a new European research consortium on coronavirus in children and pregnant women. Carlo Giaquinto, Professor at University of Padova and President of Penta, together with Professor Ali Judd at University College London, will be the scientific coordinators of VERDI.

Authors: D Sirico, CD Chiara, P Costenaro, F Bonfante, S Cozzani, M Plebani, E Reffo, B Castaldi, D Dona, LD Dalt, C Giaquinto, and GD Salvo

Published in: European Heart Journal

Abstract

A study published in the Pediatrics journal shows that children with mild forms of COVID-19 develop a greater and longer lasting antibody response than that of adults. The study involved 57 families affected by COVID-19, who were followed, as part of the study, by the Department of Women’s and Child Health at the University of Padua.

Padua – Italy, 2 July 2021 –

Authors: F Bonfante, P Costenaro, A Cantarutti, CD Chiara, A Bortolami, MR Petrara, F Carmona, M Pagliari, C Cosma, S Cozzani, E Mazzetto, GD Salvo, LD Dalt, P Palma, L Barzon, G Corrao, C Terregino, A Padoan, M Plebani, AD Rossi, D Donà, C Giaquinto

Published in: Pediatrics

Abstract

Background. Recent evidence suggests that neutralizing antibodies to SARS-CoV-2 may persist over time;

Università degli Studi di Padova, Istituto Zooprofilattico Sperimentale delle Venezie e Penta presentano nuovi dati sulla durata della protezione immunitaria contro SARS-CoV-2 nei bambini

Uno studio pubblicato in questi giorni sulla rivista “Paediatrics” dimostra che i bambini affetti da forme lievi di COVID-19 sviluppano una risposta anticorpale maggiore e più duratura di quella degli adulti.
Lo studio ha coinvolto 57 famiglie venete colpite dal COVID 19 e seguite presso il Dipartimento Salute della Donna e del Bambino dell’Università di Padova.

An Italian-led project supported by the UniCredit Foundation to study the impact of the coronavirus on children.

The project CORONA: children and COVID-19 has kicked off. Supported by the UniCredit Foundation and led by the Penta Foundation of Padua and the One Health Center of the University of Florida, the study aims to provide the national and international scientific community with new data on the impact of the pandemic on children – from a Circular Health perspective.

We recently met with Carlo Giaquinto – Penta President and Francesco Bonfante – Virologist at IZSVe to have some scientific opinion on Covid 19 testing.

In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development. He agreed to an interview with us and shed some light on our understanding of COVID-19 vaccines and how they impact children.

Read the interview here

Data gathered worldwide are increasingly suggesting that schools are not hotspots for coronavirus infections. Despite fears, COVID-19 infections did not surge when schools and day-care centres reopened after pandemic lockdowns eased. And when outbreaks do occur, they mostly result in only a small number of people becoming ill.

However, research also shows that children can catch the virus and shed viral particles, and older children are more likely than very young kids to pass it on to others.

Join this webinar, hosted by CHAI, to get highlights on key trends in the HIV space in LMICs from CHAI’s 2020 HIV Market Report.

You can expect an insightful panel discussion focusing on the resiliency of national HIV programs and markets and ensuring HIV care continuity during these trying times.

Date: November 12 2020

Time: 8am – 9am EST (13 –